Diplomatic Trade Ltd has finalized a significant cross-border investment in the Turkish pharmaceutical sector, acquiring a 49% equity stake in Farmakim ilaç Kimya Gida Ürünleri Üretim San ve Dis Tie A.S. The strategic move positions the company to transform healthcare manufacturing across the Middle East and North Africa (MENA) region.
The transaction includes plans to establish a cutting-edge bio-manufacturing facility in the United Arab Emirates by the third quarter of 2025. This facility will specialize in biosynthetic therapies, regenerative compounds, and advanced life-extension pharmaceuticals targeting growing healthcare markets in Gulf states and North Africa.
The newly formed partnership aims to leverage advanced technological capabilities, including AI-driven quality control, biocompatible packaging, and production suites that meet European Union Good Manufacturing Practice (EU-GMP) standards. This approach reflects a commitment to high-quality pharmaceutical development and production.
Institutional backing for the project comes from Morgan Brookshire LLC, a U.S.-based private family office that has structured the financing. The investment represents a significant transatlantic collaboration in life sciences and healthcare infrastructure development.
With a targeted IPO listing on a leading UAE stock exchange in the fourth quarter of 2025, early projections suggest a potential company valuation of approximately $300 million. This valuation is supported by projected EBITDA expansion, distribution rights across the Gulf Cooperation Council (GCC) region, and a robust pipeline of proprietary therapeutic treatments.
The strategic investment underscores a broader vision of enhancing pharmaceutical sovereignty and access in the MENA region. By combining Turkish manufacturing expertise with advanced UAE infrastructure and U.S. institutional capital, the partnership represents a sophisticated approach to healthcare innovation and market expansion.
This venture highlights the increasing importance of cross-border collaborations in pharmaceutical development, particularly in emerging markets. The integration of technological innovation, strategic investment, and regional market knowledge positions the new entity to become a significant player in the evolving global healthcare landscape.
